Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 97 | 6,412 | 28% |
| 2020 | 92 | 6,022 | 30% |
| 2021 | 91 | 6,918 | 32% |
| 2022 | 105 | 6,590 | 35% |
| 2023 | 103 | 6,569 | 38% |
| 2024 | 107 | 7,050 | 39% |
| 2025 from claims | – | 8,082 7,417–8,551 | 40% |
| 2026 forecast | – | 8,509 7,487–9,819 | 39% |
| 2027 forecast | – | 8,840 7,557–10,535 | 40% |
| 2028 forecast | – | 9,184 7,663–11,246 | 40% |
| 2029 forecast | – | 9,541 7,793–11,966 | 40% |
| 2030 forecast | – | 9,912 7,941–12,702 | 40% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 31% of the cases CMS names in Massachusetts; 53 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 57% hospital outpatient, 7% surgery center, 36% office. The share outside the hospital has moved −4 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 223 | 14,264−0.1%/yr | −0.1%/yr | 7.5 | 81% | 18,300 in 2030+4.2%/yr |
| Pennsylvania | 205 | 12,153+2.9%/yr | +2.9%/yr | 8.5 | 63% | 14,300 in 2030+2.7%/yr |
| New Jersey | 112 | 6,842−0.4%/yr | −0.4%/yr | 6.3 | 86% | 9,070 in 2030+4.8%/yr |
| Connecticut | 35 | 2,271−2.6%/yr | −2.6%/yr | 6.5 | 94% | 3,630 in 2030+8.1%/yr |
| New Hampshire | 34 | 2,030+2.3%/yr | +2.3%/yr | 8.7 | 67% | 3,060 in 2030+7.1%/yr |
| Maine | 16 | 850−3.9%/yr | −3.9%/yr | 5.1 | 26% | 730 in 2030−2.5%/yr |
| Rhode Island | 12 | 502+15%/yr | +15%/yr | 5.2 | 75% | 740 in 2030+6.6%/yr |
| Vermont | 9 | 412−4.3%/yr | −4.3%/yr | 3.5 | 12% | 670 in 2030+8.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 17 | 831+11%/yr | +11%/yr | 0.81.2× | 6% | 820 in 2030−0.3%/yr |
| Spinal cord & DRG stimulation | 5 | 264−7.2%/yr | −7.2%/yr | 0.30.7× | 15% | 380 in 2030+6.4%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Boston Scientific leads with 91% of company spending on these surgeons in 2025, +36 pts on 2024.
In 2025, 6 companies reported engagement with Massachusetts’s surgeons worth $140K in consulting, speaking, meals and travel tied to these products, about $1,310 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.